啟明醫療-B(02500.HK)擬投資創新醫療器械公司
格隆匯 5 月 6日丨啟明醫療-B(02500.HK)發佈公吿,為完善在結構性心臟病治療領域的戰略佈局,把握經導管介入治療技術的發展機遇,集團決定投資於一間註冊於開曼羣島的創新醫療器械公司Valgen Holding Corporation(“被投資方”或“德晉醫療”)。
德晉醫療正致力於二尖瓣反流、三尖瓣反流等病變提供系統性解決方案。德晉醫療研發了中國首款經心尖介入治療二尖瓣反流的器械MitralStitch,中國首款經股靜脈二尖瓣修復器械DragonFly-M及中國首款經股靜脈三尖瓣修復器械DragonFly-T。其中,MitralStitch、DragonFly-M已進入上市前註冊臨牀研究階段,DragonFly-T已進入探索性臨牀研究階段。
此次投資將助力德晉醫療加速其主要在研產品的臨牀研究和開發進度,使其多款產品有望成為在中國首個上市的國產創新醫療器械。二尖瓣反流和三尖瓣反流對應巨大的潛力市場,公司當前已有二尖瓣置換器械處於探索性臨牀準備階段,亦有三尖瓣置換器械處於研發設計階段,對德晉醫療的投資將會對公司產品管線佈局產生積極影響。董事會相信,憑藉此次投資,公司將進一步夯實在結構性心臟病領域的產品佈局,並通過強有力的商業化能力,在中國乃至全球市場持續保持領先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.